TNF Receptor Superfamily

Tumor necrosis factor receptor associated factors are a group of at least 6 proteins (TRAF 1-6), which are major signal transducers for the TNF receptor superfamily and the the interlukin-1 receptor/toll-like receptor (IL-1R/ TLR) superfamily. TRAF proteins are characterized by the presence of the TRAF domain at the the C-terminus,... 

Tumor Necrosis Factor a TNF Receptor Superfamily Cytokines Inflammation... 

TNF Receptor Superfamily Table appendix Receptor Proteins... 

Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies integrating mammalian biology. Cell 104 487-501... 

TNF Receptor Associated Factors TNF Receptor Superfamily Tocolytics Tolerance... 

There are two distinct types of TNF receptors, TNF-R1 (CD120a or P55) and TNF-R2 (CD120b or P75). They are implicated in inflammatory processes and both belong to the TNF receptor superfamily. TNF receptors are transmembrane proteins with intracellular domains that lack intrinsic enzymatic activity, and consequently, they require cytoplasmic proteins that help initiate the receptor-induced signaling pathways. TNF-R1 possesses an intracellular death domain and TNF-R2 interacts with molecules of the TNF receptor-associated factor 2 family (TRAF). 

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been shown to induce cell apoptosis. Through its death domain, this receptor interacts with TRADD protein, which is known to serve as an adaptor that mediates signal transduction of TNF receptors. Knockout studies in mice suggested that this gene plays a role in T-helper cell activation, and may be involved in inflammation and immune regulation. 

Smith, C. A., Farrah, T., and Goodwin, R. G. (1994). The TNF receptor superfamily of cellular and viral proteins Activation, costimulation and death. Cell ll, 959-962. 

Fas Fas/APO-l/CD95 (36kDa) is a member of the tumor necrosis factor (TNF) receptor superfamily. Fas has been shown to be an important mediator of apoptodc cell death, as well as being involved in inflammation. 

A combined phase I/II trial for ricin conjugates with antibodies against the lymphocyte activation markers CD25 (the IL-2 receptor a-chain) or CD30 (a member of the TNF receptor superfamily, possibly involved among others in memory T cell development) for patients with Hodgkin s lymphoma showed some promise [146]. 

---